Pharmaceutical giant Novo Nordisk is reportedly facing a major cybersecurity scare after hackers claimed they stole more than one terabyte of company data. The cyber group alleges that negotiations over a ransom payment failed and is now threatening to sell the information. The incident has raised concerns about cybersecurity risks facing major healthcare companies, especially those handling sensitive research, business operations and large volumes of digital data.


Hackers Claim Massive Novo Nordisk Data Breach 

The US Food and Drug Administration (FDA) on Monday (Dec 22) approved the first daily pill version of Novo Nordisk’s popular weight loss drug Wegovy, revolutionising the way to treat obesity. The move has also given the drugmaker an edge over its rival Eli Lilly, whose oral drug orforglipron, is still under review. The GLP-1 drug uses the same active ingredient, semaglutide, that powers Wegovy and its sister drug Ozempic, which is used for diabetes.Both Wegovy and Ozempic are widely used as injections. The drug mimics a natural hormone that controls appetite and feelings of fullness. While the FDA had already approved a pill to be used for treating diabetes, the approval of the weight loss drug will allow doctors to prescribe the pill to patients with obesity or those who are overweight with at least one weight-related comorbidity, such as a heart condition, the company said.“With today’s approval of the Wegovy pill, patients will have a convenient, once-daily pill that can help them lose as much weight as the original Wegovy injection,” Mike Doustdar, president and CEO of Novo Nordisk, said in a statement.According to the US Centers for Disease Control and Prevention (CDC), about 40 per cent of American adults have a prevalence of obesity. The new development was lauded by the US Obesity Care Advocacy Network (OCAN), a nonprofit advocacy group for adults with obesity.“This development represents an important opportunity for people living with obesity, offering an alternative for those hesitant to begin injectable therapy and providing a potentially lower-cost option,” the group said in a statement to AFP.According to Novo Nordisk, the Wegovy pills are expected to be available within weeks. The availability of oral pills could also expand the market for weight loss treatments and reduce costs, CBS reported, citing experts.During a clinical trial, the oral Wegovy resulted in a weight loss of 13.6 per cent of the total body weight of participants in about 15 months, which is nearly the same as injectable Wegovy, with an average weight loss of about 15 per cent.

According to Novo Nordisk, the Wegovy pills are expected to be available within weeks. The availability of oral pills could also expand the market for weight loss treatments and reduce costs

The US Food and Drug Administration (FDA) on Monday (Dec 22) approved the first daily pill version of Novo Nordisk’s popular weight loss drug Wegovy, revolutionising the way to treat obesity. The move has also given the drugmaker an edge over its rival Eli Lilly, whose oral drug orforglipron, is still under review. The GLP-1 drug uses the same active ingredient, semaglutide, that powers Wegovy and its sister drug Ozempic, which is used for diabetes. Both Wegovy and Ozempic are widely used as injections. The drug mimics a natural hormone that controls appetite and feelings of fullness. While the FDA had already approved a pill to be used for treating diabetes, the approval of the weight loss drug will allow doctors to prescribe the pill to patients with obesity or those who are overweight with at least one weight-related comorbidity, such as a heart condition, the company said. “With today’s approval of the Wegovy pill, patients will have a convenient, once-daily pill that can help them lose as much weight as the original Wegovy injection,” Mike Doustdar, president and CEO of Novo Nordisk, said in a statement. According to the US Centers for Disease Control and Prevention (CDC), about 40 per cent of American adults have a prevalence of obesity. The new development was lauded by the US Obesity Care Advocacy Network (OCAN), a nonprofit advocacy group for adults with obesity. “This development represents an important opportunity for people living with obesity, offering an alternative for those hesitant to begin injectable therapy and providing a potentially lower-cost option,” the group said in a statement to AFP. According to Novo Nordisk, the Wegovy pills are expected to be available within weeks. The availability of oral pills could also expand the market for weight loss treatments and reduce costs, CBS reported, citing experts. During a clinical trial, the oral Wegovy resulted in a weight loss of 13.6 per cent of the total body weight of participants in about 15 months, which is nearly the same as injectable Wegovy, with an average weight loss of about 15 per cent.

According to Novo Nordisk, the Wegovy pills are expected to be available within weeks. The availability of oral pills could also expand the market for weight loss treatments and reduce costs.

No injections needed! FDA approves THIS ‘once-daily’ oral weight loss pill – All you need to know

An elderly pharmaceutical executive collapsed at the White House during a press event on Thursday. The man is Gordon Findlay executive of Novo Nordisk. He collapsed as US President Donald Trump was announcing obesity drug price cuts. The man had reportedly visited the White House for the event. President Donald Trump and other dignitaries present at the White House quickly helped him.&nbsp;White House Press Secretary Karoline Leavitt later informed, “During the Most Favoured Nations Oval Office Announcement, a representative with one of the companies fainted. The White House Medical Unit quickly jumped into action, and the gentleman is okay. The Press Conference will resume shortly."

<blockquote class="twitter-tweet" data-media-max-width="560">Here&#39;s the moment a pharmaceutical executive collapsed in the Oval Office minutes ago. Reporters in the room identified him as Novo Nordisk executive Gordon Findlay, but the White House has not released a name. <a href="https://t.co/sXGwOI7asC">pic.twitter.com/sXGwOI7asC</a>&mdash; Anders Hagstrom (@Hagstrom_Anders) <a href="https://twitter.com/Hagstrom_Anders/status/1986499103228895477?ref_src=twsrc%5Etfw">November 6, 2025</a></blockquote> <script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>

The event featured top pharmaceutical executives and administration officials. Pharmaceutical company Eli Lilly and Novo Nordisk announced a deal containing the GLP-1 weight loss drug. Both companies will offer their weight-loss drug at a significant lower price.&nbsp;

Novo Nordisk executive Gordon Findlay collapsed during President Trump’s obesity drug price cut event at the White House. He is now stable.

An elderly pharmaceutical executive collapsed at the White House during a press event on Thursday. The man is Gordon Findlay executive of Novo Nordisk. He collapsed as US President Donald Trump was announcing obesity drug price cuts. The man had reportedly visited the White House for the event. President Donald Trump and other dignitaries present at the White House quickly helped him. White House Press Secretary Karoline Leavitt later informed, “During the Most Favoured Nations Oval Office Announcement, a representative with one of the companies fainted. The White House Medical Unit quickly jumped into action, and the gentleman is okay. The Press Conference will resume shortly."

Novo Nordisk executive Gordon Findlay collapsed during President Trump’s obesity drug price cut event at the White House. He is now stable.

WATCH| Shocking moment as man collapses in front of Trump in the White House obesity-drug event

Novo Nordisk has said that it will buy US pharma company&nbsp;Akero Therapeutics for a whopping $5.2 billion. The decision was made as the company wants to gain access to a promising liver disease drug.&nbsp;This is the first major deal made under the leadership&nbsp;of the CEO of the Danish firm, Mike Doustdar. He took over the reins of the company in July. His main task at the Danish firm is believed to be curbing losses of the market share to US rival Eli Lilly.&nbsp;The decision came weeks after Novo Nordisk said it would lay off 9000 people.&nbsp;Novo Nordisk is focusing on developing medicines that deal with obesity and diabetes, which can also treat cardiometabolic conditions such as MASH.&nbsp;Akero is testing its drug, efruxifermin, in a late-stage trial in patients with severe liver scarring, or cirrhosis, due to a type of fatty liver disease known as metabolic dysfunction-associated steatohepatitis (MASH, according to&nbsp;Reuters.&nbsp;If the trials are successful, this new drug could prove to be a breakthrough in the treatment of fatty liver disease, Doustdar said in a statement.&nbsp;He said it could also become a treatment for the liver condition, which can progress to more serious liver-linked problems.<h2>How much did Novo offer Akero's shareholders?</h2>Novo has offered Akero's shareholders $54 per share upfront in cash. This offer is a premium of 16.2 per cent over the share's last-known price.&nbsp;This amounts to a payment of $4.7 billion upfront. If efruxifermin secures a full U.S. approval for the condition, the Danish company will pay an additional $6 per share.&nbsp;Last year, the company bought Cardior Pharmaceuticals, which is developing a treatment for hypertension, for up to $1.1 billion.&nbsp;Some Novo investors recently told Reuters that they want to see the company invest heavily in research and development to build out its future drug pipeline and revive investor confidence.

Novo Nordisk has said that it will buy US pharma company Akero Therapeutics for a whopping $5.2 billion. The decision was made as the company wants to gain access to a promising liver disease drug.

Novo Nordisk has said that it will buy US pharma company Akero Therapeutics for a whopping $5.2 billion. The decision was made as the company wants to gain access to a promising liver disease drug. This is the first major deal made under the leadership of the CEO of the Danish firm, Mike Doustdar. He took over the reins of the company in July. His main task at the Danish firm is believed to be curbing losses of the market share to US rival Eli Lilly. The decision came weeks after Novo Nordisk said it would lay off 9000 people. Novo Nordisk is focusing on developing medicines that deal with obesity and diabetes, which can also treat cardiometabolic conditions such as MASH. Akero is testing its drug, efruxifermin, in a late-stage trial in patients with severe liver scarring, or cirrhosis, due to a type of fatty liver disease known as metabolic dysfunction-associated steatohepatitis (MASH, according to Reuters. If the trials are successful, this new drug could prove to be a breakthrough in the treatment of fatty liver disease, Doustdar said in a statement. He said it could also become a treatment for the liver condition, which can progress to more serious liver-linked problems. How much did Novo offer Akero's shareholders? Novo has offered Akero's shareholders $54 per share upfront in cash. This offer is a premium of 16.2 per cent over the share's last-known price. This amounts to a payment of $4.7 billion upfront. If efruxifermin secures a full U.S. approval for the condition, the Danish company will pay an additional $6 per share. Last year, the company bought Cardior Pharmaceuticals, which is developing a treatment for hypertension, for up to $1.1 billion. Some Novo investors recently told Reuters that they want to see the company invest heavily in research and development to build out its future drug pipeline and revive investor confidence.

Novo Nordisk-Akero Therapeutics deal: Novo Nordisk is focusing on developing medicines that deal with obesity and diabetes, which can also treat cardiometabolic conditions such as MASH.

Novo Nordisk to buy Akero Therapeutics for $5.2 billion over liver drug

Novo Nordisk's Attempt to Overtake Rival Eli Lilly in the Booming Obesity Medicine Market Fails. This Led to the Company's Shares Falling by a Record on Friday.

Novo Nordisk's New Weight Drug Disappoints

Novo Nordisk's Attempt to Overtake Rival Eli Lilly in the Booming Obesity Medicine Market Fails.



This Led to the Company's Shares Falling by a Record on Friday.



Novo Nordisk.. Danish pharmaceutical company which is known for several medicines involving weight loss is all set to enter the Chinese market.. Watch in for more details!

Novo Nordisk introduces Wegovy amid soaring obesity rates

Firefighters battling a large fire on Wednesday at an office building belonging to Danish pharmaceutical group Novo Nordisk, maker of weight loss drugs Ozempic and Wegovy, said it was under control after several hours.

The blaze, initially described as a "massive fire" involving 100 firefighters, was after more than three hours "under control and we have gone down to about 30 firefighters," fire brigade chief of operations Martin Smith told AFP.

Everyone had been evacuated from the building and there were no injuries, he said.

Large plumes of grey smoke could initially be seen 30 kilometres (18 miles) from the fire in Bagsvaerd, in the northern part of greater Copenhagen, Danish news agency Ritzau reported.

"Now it's just pockets of smoke," Smith told AFP, adding that bulldozers and cranes were being called in to "clear the debris and finish the job".

Novo Nordisk said in a statement the smoke was not toxic.

"A fire broke out today outside a building at Novo Nordisk's site in Bagsvaerd, and it has spread to an adjacent office building," it said.

"The smoke is not toxic, and there are no injuries," it added.&nbsp;

Smith said the blaze broke out in a container at a Novo Nordisk construction site, and spread to the roof of its adjacent office building.

He expected firefighters to continue working for four to six more hours.

The fire came less than a week after a blaze erupted on May 16 at another Novo Nordisk site under construction in Kalundborg, which had no impact on its drugs production.

Firefighters battling a large fire on Wednesday at an office building belonging to Danish pharmaceutical group Novo Nordisk, maker of weight loss drugs Ozempic and Wegovy, said it was under control after several hours.

Firefighters battling a large fire on Wednesday at an office building belonging to Danish pharmaceutical group Novo Nordisk, maker of weight loss drugs Ozempic and Wegovy, said it was under control after several hours. The blaze, initially described as a "massive fire" involving 100 firefighters, was after more than three hours "under control and we have gone down to about 30 firefighters," fire brigade chief of operations Martin Smith told AFP. Everyone had been evacuated from the building and there were no injuries, he said. Large plumes of grey smoke could initially be seen 30 kilometres (18 miles) from the fire in Bagsvaerd, in the northern part of greater Copenhagen, Danish news agency Ritzau reported. "Now it's just pockets of smoke," Smith told AFP, adding that bulldozers and cranes were being called in to "clear the debris and finish the job". Novo Nordisk said in a statement the smoke was not toxic. "A fire broke out today outside a building at Novo Nordisk's site in Bagsvaerd, and it has spread to an adjacent office building," it said. "The smoke is not toxic, and there are no injuries," it added. Smith said the blaze broke out in a container at a Novo Nordisk construction site, and spread to the roof of its adjacent office building. He expected firefighters to continue working for four to six more hours. The fire came less than a week after a blaze erupted on May 16 at another Novo Nordisk site under construction in Kalundborg, which had no impact on its drugs production.

Fire at Danish pharma giant Novo Nordisk 'under control'

Novo Nordisk, the maker of the weight-loss drug Wegovy, has become the most valuable firm in Europe, dethroning French luxury conglomerate LVMH. According to a report by BBC on Tuesday (September 5), Novo Nordisk's shares rose after it launched Wegovy in the United Kingdom (UK).

Novo Nordisk, the maker of the weight-loss drug Wegovy, has become the most valuable firm in Europe, dethroning French luxury conglomerate LVMH. According to a report by BBC on Tuesday (September 5), Novo Nordisk's shares rose after it launched Wegovy in the United Kingdom (UK). The report said that at the close of trading on Monday, Novo Nordisk had a stock market valuation of $428 billion. The report further said that the drug was available in the UK's public healthcare system and also on the private market. What is Wegovy? Wegovy is an injectable prescription medicine that may help adults and children aged ≥12 years with obesity. As per Novo Nordisk's website, Wegovy is prescribed for adults with excess weight who also have weight-related medical problems to help them lose weight and keep it off. Also read | Novo Nordisk says its weight loss drug Wegovy can cut risk of heart attack by 20% Novo Nordisk says that the drug should be used with a reduced-calorie meal plan and increased physical activity. BBC reported some famous personalities, including business magnate Elon Musk use Wegovy. What are the side effects of Wegovy? Some of the most common side effects of Wegovy include nausea, diarrhoea, constipation, vomiting, and heartburn. Novo Nordisk's website states some of the most serious side effects can include possible thyroid tumours, including cancer. "In studies with rodents, Wegovy and medicines that work like Wegovy caused thyroid tumours, including thyroid cancer. It is not known if Wegovy will cause thyroid tumours or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people," the website adds. WATCH WION LIVE HERE You can now write for wionews.com and be a part of the community. Share your stories and opinions with us here.

Maker of weight-loss drug Wegovy is now Europe's most valuable firm

novo-nordisk

Novo Nordisk, News on Novo Nordisk, stories on Novo Nordisk, articles on Novo Nordisk, Novo Nordisk stories at Wion, Novo Nordisk news, Novo Nordisk latest news

novo nordisk

Hackers Claim Massive Novo Nordisk Data Breach

No injections needed! FDA approves THIS ‘once-daily’ oral weight loss pill

WATCH| Man collapses in front of Trump in the White House obesity-drug event

Novo Nordisk to buy Akero Therapeutics for $5.2 billion over liver drug

Novo Nordisk's New Weight Drug Disappoints

Novo Nordisk's New Weight Drug Disappoints

Novo Nordisk introduces Wegovy amid soaring obesity rates

Fire at Danish pharma giant Novo Nordisk 'under control'

Maker of weight-loss drug Wegovy is now Europe's most valuable firm